- Home
- HQL vs ALLO Comparison
HQL vs ALLO Comparison
Compare HQL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQL
- ALLO
- Stock Information
- Founded
- HQL 1992
- ALLO 2017
- Country
- HQL United States
- ALLO United States
- Employees
- HQL N/A
- ALLO N/A
- Industry
- HQL Investment Managers
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQL Finance
- ALLO Health Care
- Exchange
- HQL Nasdaq
- ALLO Nasdaq
- Market Cap
- HQL 368.7M
- ALLO 371.8M
- IPO Year
- HQL N/A
- ALLO 2018
- Fundamental
- Price
- HQL $11.98
- ALLO $1.17
- Analyst Decision
- HQL
- ALLO Strong Buy
- Analyst Count
- HQL 0
- ALLO 10
- Target Price
- HQL N/A
- ALLO $9.66
- AVG Volume (30 Days)
- HQL 120.9K
- ALLO 3.0M
- Earning Date
- HQL 01-01-0001
- ALLO 05-13-2025
- Dividend Yield
- HQL 11.56%
- ALLO N/A
- EPS Growth
- HQL N/A
- ALLO N/A
- EPS
- HQL 0.79
- ALLO N/A
- Revenue
- HQL N/A
- ALLO $22,000.00
- Revenue This Year
- HQL N/A
- ALLO N/A
- Revenue Next Year
- HQL N/A
- ALLO $9.07
- P/E Ratio
- HQL $17.08
- ALLO N/A
- Revenue Growth
- HQL N/A
- ALLO N/A
- 52 Week Low
- HQL $11.34
- ALLO $1.09
- 52 Week High
- HQL $14.37
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- HQL 42.81
- ALLO 38.89
- Support Level
- HQL $11.88
- ALLO $1.09
- Resistance Level
- HQL $13.09
- ALLO $1.78
- Average True Range (ATR)
- HQL 0.28
- ALLO 0.14
- MACD
- HQL -0.01
- ALLO -0.03
- Stochastic Oscillator
- HQL 9.76
- ALLO 27.46
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.